Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions

Haroon, Muhammad; Chaudhry, Adnan Bin Rafiq; FitzGerald, Oliver

doi:10.3899/jrheum.150757

Cited by 23 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data confirm the high prevalence of metabolic syndrome in PsA ( 27 , 28 ). Since metabolic syndrome is a combination of cardiovascular risk factors, it is a marker of cardiovascular risk.…”

Section: Discussionsupporting

confidence: 88%

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

et al. 2022

View full text Add to dashboard Cite

BackgroundPsoriatic arthritis (PsA) is associated with increased cardiovascular morbidity and mortality. The aims of our real-life study were to compare the prevalence of cardiovascular risk factors (CVRFs) and cardiovascular events (CVEs) among patients with PsA with a control population, to evaluate the impact of correcting factors in equations that assess cardiovascular risk (CVR) in PsA, and to determine the percentage of patients who reach the LDLc target as indicated by the European guidelines.MethodsIn this observational cross-sectional monocentric case-control study, we used a standardized procedure to systematically assess patients with PsA aged 25–85 years who met the Classification for Psoriatic Arthritis (CASPAR) criteria. Controls were extracted from the MOnitoring NAtionaL du rISque Artériel (MONALISA) study. We compared the prevalence of CVRFs, CVEs, the CVR, and the percentage of patients reaching recommended LDLc target in both populations. The CVR was first assessed using SCORE and QRISK2 equations. Then, the SCORE equation was corrected by applying a 1.5 multiplication factor, as recommended by EULAR for rheumatoid arthritis (SCORE-PsA), and the QRISK2 was corrected using the “rheumatoid arthritis” item (QRISK2-PsA).ResultsA total of 207 PsA and 414 controls were included. CVRFs and CVEs were more frequent in the PsA group. After controlling for age and gender, atherothrombotic disease was increased in the PsA population (SCORE p = 0.002, QRISK2 p = 0.001). Using the SCORE-PsA increased the percentage of patients with a high or very high CVR from 39.3 to 45.3% in the PsA group. Similarly, using the QRISK2-PsA increased the percentage of patients with a CVR ≥ 10% from 44.9 to 53.2%. The percentages of patients with PsA with high LDLc in the high and very high CVR groups were not significantly different from controls, despite a trend in favor of patients with PsA. Of the 83 PsA with a QRISK2 ≥ 10%, only 22.9% were treated with statin vs. 35.8% of the 134 controls. The QRISK2-PsA score did not alter these results.ConclusionIn real-life, patients with PsA have a higher prevalence of CVRFs, as well as a higher prevalence of CVEs compared to the general population. The CVR is higher in the PsA population than in the controls either using the SCORE and QRISK2 equations or using the corrected SCORE- PsA and QRISK2-PsA equations.

show abstract

Section: Discussionsupporting

confidence: 88%

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It is well known that metabolic syndrome is a common disorder among PsA patients (3,4). In this study, metabolic syndrome was seen in 21 patients (24.4 %), which was a lower rate than previously reported in literature (29,30).…”

Section: Discussioncontrasting

confidence: 53%

Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis

Çolak¹,

Omma²,

Sandıkçı³

et al. 2019

BLL

View full text Add to dashboard Cite

OBJECTIVES: To examine the relationship between disease activity and vaspin, neutrophil gelatinase-associated lipocalin (NGAL) and apolipoprotein levels in patients with psoriatic arthritis (PsA). BACKGROUND: Psoriatic arthritis (PsA) is a chronic infl ammatory arthritis, which is related with psoriasis. Adipokines are the mediators which play a role in metabolic homeostasis and infl ammatory conditions. METHODS: The levels of vaspin, NGAL, apolipoproteins and their correlations with disease activity were compared in 50 psoriatic arthritis patients and 36 healthy controls. RESULTS: The levels of vaspin, NGAL and apolipoprotein B/A1 ratio were signifi cantly higher in the patient group (p < 0.05). Apolipoprotein A1 was lower in the patients with PsA compared to the healthy control group. There was no signifi cant correlation between disease activity and adipokines or metabolic parameters (p > 0.05). CONCLUSION: This is the fi rst study to have compared vaspin and NGAL levels in patients with PsA. Vaspin and NGAL can be used as a biomarker in PsA. Vaspin, NGAL and dyslipoproteinemia are not correlated with disease activity (Tab.

show abstract

“…In a recent cross-sectional assessment of 283 PsA patients, we have shown that 74% had elevated blood pressure [46] with prevalence of hypertension in PsA significantly higher compared to the patients with non-inflammatory rheumatologic conditions (74 vs. 57%, p = 0.002) [47]. In another study, using a large population-based cohort (UK biobank), it has been shown that CVD outcomes, in particular hypertension, are significantly higher in PsA compared to psoriasis and is independent of known CVD risk factors [48].…”

Section: Hypertensionmentioning

confidence: 83%

Cardiovascular Comorbidities in Psoriatic Disease

Simonyi

Haroon²,

FitzGerald

2019

Rheumatol Ther

Self Cite

View full text Add to dashboard Cite

Psoriatic disease (PsD) is a multisystem inflammatory disorder with a high prevalence of cardiovascular (CV) risk factors contributing to accelerated atherosclerosis and its sequelae. Imaging studies, notably with ultrasound, computed tomography, and positron emission tomography (PET) scanning have confirmed significant atherosclerotic change with plaque formation and vessel stenosis. Atherosclerosis is likely driven by a combination of traditional risk factors which occur more frequently in PsD and by systemic inflammation with associated pro-inflammatory cytokine production. While the mechanisms driving atherosclerosis in PsD are incompletely understood, it is now best practice to try to minimize the impact of CV risk factors by regular assessment, prevention, and treatment and also by ensuring that inflammatory musculoskeletal and cutaneous disease is adequately suppressed. Future studies need to focus on improving our understanding of the mechanisms driving atherosclerosis and, as a consequence, developing more rationale approaches to prevention and treatment.

show abstract

Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions

Cited by 23 publications

References 11 publications

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis

Cardiovascular Comorbidities in Psoriatic Disease

Contact Info

Product

Resources

About